Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)

Next Previous
Trial Profile

A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eltrombopag (Primary)
  • Indications Thrombocytopenia
  • Focus Therapeutic Use
  • Acronyms ASPIRE
  • Sponsors GlaxoSmithKline; Novartis Pharmaceuticals

Most Recent Events

  • 06 Nov 2019 Results assessing the long-term durability of clinical benefit, overall survival (OS) and progression-free survival (PFS) for Part 2 patients within Part 2 and Part 3, and safety and tolerability of eltrombopag monotherapy in patients with advanced MDS or AML, were released at the 61st Annual Meeting and Exposition of the American Society of Hematology.
  • 06 May 2016 Status changed from active, no longer recruiting to completed.
  • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top